<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521753</url>
  </required_header>
  <id_info>
    <org_study_id>R-2014-785-056</org_study_id>
    <nct_id>NCT02521753</nct_id>
  </id_info>
  <brief_title>Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients</brief_title>
  <acronym>OMgObPCOS</acronym>
  <official_title>Effect Polyunsaturated Fatty Acids or Magnesium in Metabolic, Hormonal, and Inflammatory Profile in Obese Women With Polycystic Ovary Syndrome. A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in reproductive age
      women. PCOS is usually characterized by an excessive androgen production, menstrual
      irregularities, and polycystic ovaries. Women with PCOS are often obese and have a varying
      degree of insulin resistance (IR). Weight reduction constitutes the initial treatment for
      these patients. Metformin has proven to be useful in IR and is frequently used in PCOS.
      However metformin use may be accompanied by gastrointestinal discomfort, and a high abandon
      rate. Other therapeutic alternatives such as magnesium and polyunsaturated fatty acids have
      been used in other IR states and may be useful in PCOS. The aim of this study is to asses the
      efficacy of these alternatives in obese PCOS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic Ovary Syndrome (PCOS)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The study is open label. No blindness for participant or investigator is used</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic profile</measure>
    <time_frame>Six months after intervention</time_frame>
    <description>Serum concentration of metabolic biomarkers (glucose, insulin, triglycerides, cholesterol, HDL, M and M/I value derived from a euglycemic clamp)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormonal profile</measure>
    <time_frame>Six months after intervention</time_frame>
    <description>Serum concentration of hormones [Testosterone, dehydroepiandrosterone sulphate (DHEAs), sex hormone-binding globulin (SHBG), free androgen index (FAI)]</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 850mg twice a day for six months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium chloride 250mg daily for six months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUFA omega 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Intervention also includes weight reduction diet and exercise therapy</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium</intervention_name>
    <description>Intervention also includes weight reduction diet and exercise therapy</description>
    <arm_group_label>Magnesium</arm_group_label>
    <other_name>Nature made magnesium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PUFA</intervention_name>
    <description>Intervention also includes weight reduction diet and exercise therapy</description>
    <arm_group_label>PUFA omega 3</arm_group_label>
    <other_name>Omega 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Polycystic Ovary Syndrome according to Rotterdam criteria,

          -  BMI ≥ 27 Kg/m2

        Exclusion Criteria:

          -  Type 2 diabetes mellitus,

          -  in treatment for polycystic ovary syndrome features
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mardia Guadalupe López Alarcón, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mardia Guadalupe López Alarcón, MD, phD</last_name>
    <phone>(005255) 56276944</phone>
    <email>marsau2@produgy.net.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Gineco Obstetricia Centro Médico &quot;La Raza&quot;</name>
      <address>
        <city>Mexico City</city>
        <state>D.f.</state>
        <zip>2990</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor S Vital-Reyes, MD, PhD</last_name>
      <phone>52 55 57245900</phone>
      <phone_ext>23719</phone_ext>
      <email>vitalito23@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Mardia Guadalupe Lopez Alarcon</investigator_full_name>
    <investigator_title>Investigador titular B</investigator_title>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Obesity</keyword>
  <keyword>Metformin</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Polyunsaturated fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

